Lv41
420 积分 2026-07-01 加入
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
7小时前
待确认
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
7小时前
待确认
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
7小时前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
7小时前
待确认
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
17小时前
已完结
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
17小时前
已完结
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
17小时前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
17小时前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
18小时前
已完结
皖公网安备34019202002308
